Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call is being recorded. I would now like to turn the call over to Cameron Radinovic of Burns McClellan. Mr. Radinovic, please go ahead. Thank you. Good morning, and welcome to the LENSAR Third Quarter 2023 Financial Results Conference Call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended September 30, 2023. This press release is available on the Investor Relations section of the company's website at www.lensar.com. Joining me on the call today is Nick Curtis, Chief Executive Officer of LENSAR, who will review the company's recent business and operational progress. Following his comments, Tom Staab, Chief Financial Officer of LENSAR, will provide an overview of the company's financial highlights before turning the call back over to the operator to facilitate answering any questions you may have. Today's conference call will contain certain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause the company's actual results, performance, or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of the company's risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on the website. In addition, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 9, 2023. LENSAR undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live conference call. It's my pleasure to turn the call over to Nick Curtis. Nick? Thank you, Cam, and good morning to everyone. Thank you for joining us on our Third Quarter 2023 Conference Call. I'm pleased to report that we have maintained our momentum through the third quarter of this year with 11 new ALLY systems installed and strong year-over-year growth in procedure volume, driven primarily by the continued adoption of ALLY in the U.S. Through the first nine months of 2023, we placed 29 ALLY systems and have exceeded our previously stated objective of 30 installations. Additionally, we exited the quarter end September 30th, with a backlog of eight ALLY systems pending installation. Our third quarter revenue increased 26% over the same quarter in 2022, which was supported by both robust system sales and an increase in lease revenue. We continued to make headway into private equity-owned or managed ophthalmology groups, which remain core to our growth strategy based on their size, scale, and their focus to on improved efficiencies. ALLY is significantly reducing treatment times, improving patient throughput and treatment workflow, and most importantly, increasing revenue and EBITDA for practices at ASCs. This leads to an accelerated return on investment of ALLY compared to the other competitive systems. As a result, we're seeing multiple ALLY installations with facilities that have placed an ALLY unit in each OR. Our ALLY installed base totals 39 systems as of the end of the third quarter across 31 surgical sites, with three sites having more than one system in use. We expect this trend to continue as surgeons present the results of several time and motion studies conducted in multiple facilities that demonstrate surgeon's time savings of up to seven minutes and staff time savings of up to 18 minutes compared to competitive systems. These savings are realized for patients as well, with patients spending up to nearly 1 hour less in the surgical facility during their cataract procedure. Importantly, when looking at year-over-year growth globally, we observed a substantial 20% increase in total revenue during the first three quarters of 2023 when compared to 2022. This growth is particularly remarkable given the challenges posed by ongoing third-party payer reimbursement issues in South Korea, which have driven our revenue in that region down to zero. In the U.S. market, which remains our primary area of focus in the near term, procedure volumes increased 16% over the third quarter of 2022, while procedures among users who transitioned from our previous generation LENSAR laser system to ALLY or added ALLY to an existing LLS deployment increased 12% over the third quarter of last year. Importantly, the ongoing consistent adoption of ALLY and continued growth in utilization is yielding in further market share gains for LENSAR in the third quarter. According to the most recent data from Market Scope, an estimated 16.4% of all U.S. femtosecond laser-assisted cataract surgery procedures in the third quarter of 2023 were performed using a LENSAR system. By comparison, our market share in the third quarter of 2022, when we were launching ALLY, was 14.1%. This equates to a 2.3% procedure market share growth in the first year of ALLY's launch. Given our size, the gains we have achieved are impressive and exciting and further confirm the value that ALLY is delivering economically, operationally, and clinically for surgeons. We recently participated in the American Academy of Ophthalmology Congress over the weekend, and while the overall meeting turnout was moderate, we successfully conducted a remarkable 66 demos. These demos spanned across 54 practices, ambulatory surgery centers, and various institutions, eager to explore the potential of ALLY in their practices and centers. This underscores the growing enthusiasm for the economic and clinical advantages that ALLY brings. These demonstrations are one of several key initiatives in expanding the LENSAR pipeline. Furthermore, our financing last quarter has enabled us to begin the process of hiring additional sales managers and sales development representatives to scale the LENSAR business and ALLY's footprint. The SDR is an important new role within our organization. This team's objective is to identify, educate, cultivate, and deliver qualified leads to our sales managers. Specifically, our SDRs are responsible for initiating personalized discussions with targeted high-volume, competitive femtosecond laser-assisted cataract surgery surgeons and high-volume premium femto-naive cataract surgeons who have engaged in our digital campaigns with the goal of cultivating these relationships to shorten the sales cycle and set up appointments for our sales managers. This initiative expands our marketing efforts in a meaningful way. Our targeted approach to the market has resulted in nearly 50% of our installs in 2023 being in accounts who were previously using a competitive femtosecond laser, and 74% of our surgeon demos during the AAO were conducted with competitive femtosecond laser users. This strategy will continue to lead to an expansion of our system footprint and procedure market share. The increase in our sales force and SDRs will allow us to expand our outreach in the market. Looking ahead, in addition to expanding ALLY's commercial footprint in the U.S., in the coming months, we expect to receive the first ALLY marketing authorizations and begin ALLY's international launch outside the U.S. through our distribution partners. As a reminder, we submitted our application for European Union certification of ALLY in the third quarter of 2022. We remain in close contact with our distributors in Europe and elsewhere, and the enthusiasm toward ALLY in their respective markets is significant. We believe that we're well-positioned to replicate the early success we've seen in the U.S. abroad. We look forward to realizing ALLY's full potential to be a global disruptive technology by becoming the dominant femtosecond laser system for premium refractive cataract surgery. Surgeons are recognizing that the time is getting closer, and there is a need to begin replacing their old femtosecond lasers. In addition, practices that have never performed femtosecond laser surgery are beginning to understand how LENSAR ALLY system is addressing the limitations of the first-generation lasers that have been predominant in the market in the past. We believe that LENSAR is in a strong position to continue executing on our key strategic initiatives aimed at maximizing the success of ALLY. Now, let me turn the call over to Tom to cover our financial highlights for the quarter. Tom? Thank you, Nick. Our third quarter 2023 financial results are included in our press release issued earlier this morning, but I'd like to make some brief remarks on certain items to provide additional detail. Revenue was $9.8 million in the third quarter of 2023, compared to $7.7 million in the third quarter of 2022, reflecting a 26% increase. As Nick mentioned, the increase was primarily due to increased system sales, but we generated growth in service and lease revenue as well. We had a solid quarter of system placements and expect to place even more systems in the fourth quarter based upon ALLY demand. Accordingly, we expect to exceed the 11 ALLY systems installed in the third quarter. We have installed 29 ALLY systems through the first nine months of 2023, and a total of 39 systems from ALLY's launch in August of last year. As Nick mentioned, third-party reimbursement issues in South Korea continue to be a drag on our quarterly results. Historically, South Korea has represented approximately 10% of our revenue, and revenue from this region has been non-existent for over a year. Furthermore, we are limited to the United States as our only significant operating region in which to sell ALLY. We look forward to receiving European clearance, as well as clearance in some other small operating regions in 2024. Once we receive clearance in Europe, we expect placement numbers to increase significantly as ALLY would then be cleared in two significant operating regions. We continue to watch South Korea and are pursuing clearance in that region, too. It was previously a significant operating region for us prior to third-party reimbursement issues, and we expect the region to return once again to being a significant contributor to our revenue in the future. However, we cannot predict the timing of when South Korea will return to significance due to the nature of the ongoing dispute. We would like to have ALLY cleared and prepared to launch in South Korea when third-party reimbursement issues are resolved, and we are preparing for that eventuality. Gross margin for the quarter was $4.9 million, representing a gross margin of 50%, compared to $3.9 million and a 50% gross margin realized in the third quarter of 2022. This matches our previously issued guidance of the low 50s and represents the larger mix of ALLY sales and revenue that carry a lower gross margin percentage than procedure sales. We continue to expect the low 50s for a gross margin percentage for 2023, and are currently sitting at 53% for the nine months. Total operating expenses for the third quarter of 2023 were $6.9 million, compared to $8 million in the third quarter of 2022. The decrease in operating expenses was primarily attributable to significantly lower selling, general, and administrative costs associated with our recording of an Employee Retention Credit that offset approximately $1.4 million of expense. This ERC reimbursement was fully recorded in the third quarter, and so no future credit is expected with this program. We intend to expand our selling organization to scale the business and drive continued ALLY growth. As mentioned in prior quarters, we will continue to innovate and invest in ALLY research and development, but we expect our R&D expenditures to be relatively stable quarter- to- quarter, with our 2023 annual investment in R&D to approximate $7 million. Net income for the quarter was $2.6 million, or $0.13 per common share, reflecting an increase over a $4 million loss and a $0.39 loss per common share in the third quarter of 2022. Our net income for the quarter was attributable to a change in fair value of our warrant liability, which created a $4.3 million gain in the quarter. Our warrant liability and the related quarterly adjustment will continue to be reported in our Adjusted EBITDA presentation to allow a complete understanding and transparency of our quarterly results. As of September 30, 2023, we had cash and cash equivalents of $24.9 million, as compared to $14.7 million on December 31st, 2022. Cash used in the quarter was $500,000. That ends my remarks. Now I'd like to turn the call back over to Krista, and we look forward to your questions. If you would like to ask a question, please press star one on your telephone keypad. Your first question comes from the line of Ryan Zimmerman from BTIG. Please go ahead. Good morning, and thanks for taking the questions, guys. I guess, you know, to start on ALLY, it sounds like, you know, you're really having good momentum here. Maybe just to start, Nick, for you on feedback on ALLY and kind of your existing user base. I mean, I appreciate all the time-saving metrics you're giving, but just maybe more qualitatively, kind of what you're hearing from the field about their use of ALLY, how they think about it in, you know, the context of other systems. And then I have some other follow-ups. Sure. Thanks, Ryan. I appreciate the questions. So, you know, about half of our business today is coming from new users to LENSAR. And most of those customers have been using the older competitive systems. And so to a T, the whole time and motion savings equating to a higher efficiency, and depending on the practice and how busy they are and maybe how many users there are, either doing significantly more cases in a given surgical day, or the ability to have better staff satisfaction in reducing the overhead by letting people go early, they finish their day early. And so there's not a practice that hasn't experienced that in the same way. The other thing that's significant, I mentioned that three accounts, you know, which is, you know, close to 10% already, have more than one system installed in the practice or moving to the idea where they're putting one in each operating room. We didn't expect that to happen in the first 12 months, 18 months, you know, before, you know, people would do that. And so very quickly, where I felt like people would be—were pretty invested with their competitive systems in the feeder model, with the system sitting outside of the operating room, given the ergonomics and what they're seeing with ALLY, the desire to want to move into the operating room and save even more time and staff touches, if you will, in this is evident. So, from that perspective, across the board on the competitive user side, you know, they are anxious. And so it's kind... not really like an if, it's kind of a when. Like, people are trying to figure out, you know, based on- Mm-hmm ... their own economics, when it might make sense for them to make the switch over. Okay. Any other questions? You know, maybe to-- Yeah, no, that was, that was great, Nick. And then, you know, I have a couple others. I'm going to keep rolling here. But Tom, I mean, it looks like there was limited leasing. I mean, you still grew leasing this quarter, but limited leasing. And, you know, if I just step back and think about kind of, you know, the health of your customer base, you know, it, it seems like you're not seeing any impact on capital demand, particularly in terms of the outright sale dynamics of the system... relative to maybe people, you know, I guess I would think more people would, would want to lease it, although, you know, with rates higher, maybe that's not the case. I'm just curious if you can kind of comment on kind of how you think about the macro environment, you know, in ophthalmic practices today in terms of capital demand and, and kind of what, what your mix of sales versus lease says about the customer base. Well, I think there's two observations, Ryan. One is, you know, the macro environment for large capital purchases has certainly soured because of interest rates and just the overall economy. So I think what that shows us is just the strong desire to use ALLY as a system. And there's an appreciation by those users that there is significant benefit over the competitive users or competitive systems. I think that, right now, earlier in the launch, you're seeing a heavier contingent of those high femto volume users converting, and they want to do even more cases faster and better the economics. I'm not so sure that in the future, that you're going to see that, you know, the heavier mix on sales, just because you can't discount the macroeconomic environment, and that is a headwind for us. But we've been very, very successful in the past, and it's just hard to predict, you know, where that percentage is going to go. But if you pressed me, I would say the leasing percentage is probably going to be a higher part of the ALLY mix. And, you know, obviously, I think what you're going to see is the more ALLY systems we get out there, the more cross-pollination between physicians and the ability for a physician to go in and see how successful the practice has become and how much faster and better they can do these procedures. And so peer-to-peer conversation and observation is just, it's worth its weight in gold, and it's the best marketing that can happen. And so, you know, it's, it's like that commercial, you know, when the, you know, he tells somebody else and, you know, it just, it just expands from there. Sure. And so the more systems we get out, the more demand you're going to see for ALLY, just because of that cross-pollination. Okay. Very good. And then, a couple for me, a couple more for me. So I saw Oertli submitted its 510(k), I think that was public, last week at AAO, for the phacoemulsification component. I'm just wondering, Nick, if you want to comment on kind of, you know, when they could potentially be on the market with that and how it impacts, you know, maybe either the customer base or commercialization plans in the future. Yeah, another good question, Ryan. Thanks. They did submit their 510(k) for the Faros device, and Faros is going to be our predicate device for the optional, let's say, phacoemulsification option to the ALLY. And so customers can either retrofit the ALLY, the Faros system into their current ALLY, if they have ALLY in the field today without it, and or they can order it with the phaco device when they order their ALLY to begin with. Either way, this will be optional for LENSAR customers on a going-forward basis. We would expect that... You know, I'm a little reticent to comment too much on what is Oertli's, you know, business and really under their control as it relates- Sure ... to the clearance of the device. But suffice to say that, you know, FDA has 180 days, you know, with a file, and that can move slightly depending on, you know, the questions and when Oertli responds with the response. And so, you know, you- Yeah ... just to suffice to say, you know, a bit somewhere between now and 180 days, if they're going to get the clearance, they would get a clearance, and then we would take their data and use that data in our own 510(k) submission for the ALLY. So I wouldn't expect that it would be, you know, an option for LENSAR customers until sometime much later in 2024, assuming that Oertli gets their a timely- Yeah ... sort of, yep. Okay, fair enough. And then last one for me. The additional salespeople you're planning to hire and some of these new roles, I appreciate your color on that. Just help us understand kind of, you know, what that cadence looks like, when those people, you know, you expect to potentially have those people in place, when they could be productive, and just how to think about that impact from, you know, the additional salespeople, as we move into 2024. Yep, thanks. Given the interest that we're seeing in ALLY right now and sort of the activity level, where it's going, to be honest, I wish I had them yesterday. And so I'm pretty excited about the fact that we're, you know, we're gonna scale here, you know, quite a bit. I would say that between now, you know, given the cycle of interviews, holidays coming and whatnot, realistically, I'd say it's between now and, let's say, the end of the first quarter in 2024, from, you know, bringing on board and scaling. And people also have with their current jobs, you know, year-end sort of cleanup and bonuses and stuff. you know, I would expect that by the end of the first quarter, we would have several new hires in place there. We should be bringing on a second SDR here, within the next 30 days or so. ... and, if not before then. And so, and the SDR has been really an interesting and key position for us in terms of generating the leads and setting up of the sales appointments, which is really, you know, causing our current sales people, they have to run hard because, you know, they cover large geographies now, and so these leads are coming from all over. So, you know, really excited about that. We're also considering a distributor up in the upper Midwest area that has a good reach into several different states up there, and sort of a mix in with our direct employees. Got it. All right. Good. Thank you for taking my questions. Thank you, Ryan. Appreciate it. Again, if you'd like to ask a question, please press star one on your telephone keypad. We have no further questions in the queue at this time. I will now turn the call over to Curtis for closing remarks. Thank you. Appreciate everybody joining our call today. As you can tell, we're really excited as to what's going on here with LENSAR now, and I appreciate your continued interest in what we're doing. We really look forward to updating you as we continue to make further progress for the exciting remainder of 2023. Stay tuned, folks. Thank you. This concludes today's conference call. Thank you for your participation, and you may now disconnect.